Akiram Therapeutics to present promising data on the therapeutic potential of its drug candidate at EANM Congress
Akiram Therapeutics, a Swedish biotech company specializing in radiotherapy will present promising preclinical data at the European Association of Nuclear Medicine (EANM) Congress taking place in Vienna, Austria on September 9–13. The data showcases the potential of the company’s radiopharmaceutical [177]Lu-AKIR001 targeting tumor lesions for therapeutic purposes. A Phase 1 study is planned for 2024.Akiram Therapeutics has developed a new type of targeted radioimmunotherapy, [177]Lu-AKIR001. The therapy has shown promising results in several preclinical studies and holds the potential to